Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
Edward M. Sellers, Deborah B. Leiderman
Clinical Pharmacology & Therapeutics August 24, 2017 DOI: 10.1002/cpt.776 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychotomimetic Hallucinogen Illusion Variety cybernetics Pharmacology Artificial intelligence |
| Citations | 27 |
| Key findings | Obtaining approval to market a restricted psychotomimetic agent is formidable. |
Abstract
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.